Compare DFLI & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | LITS |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 41.5M |
| IPO Year | N/A | N/A |
| Metric | DFLI | LITS |
|---|---|---|
| Price | $2.05 | $1.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 378.4K | 236.0K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.95 |
| 52 Week High | $5.15 | $3.03 |
| Indicator | DFLI | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 50.84 |
| Support Level | $1.56 | $1.17 |
| Resistance Level | $2.24 | $1.26 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 49.98 | 54.05 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.